# Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

Study · id `cardio:ct-nct02551172` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02551172](<https://clinicaltrials.gov/study/NCT02551172>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02551172

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 270 participants.

## Technical summary

Registry record NCT02551172. Randomized; double masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 270 participants (planned count; ClinicalTrials.gov record NCT02551172, source copy `cardio:ctgov-nct02551172-2015-09-16`, retrieved 2026-10-31)
- Start date: 2014-10 (registry gives no type) (ClinicalTrials.gov record NCT02551172, source copy `cardio:ctgov-nct02551172-2015-09-16`, retrieved 2026-10-31)
- Primary completion: 2016-01 (anticipated) (ClinicalTrials.gov record NCT02551172, source copy `cardio:ctgov-nct02551172-2015-09-16`, retrieved 2026-10-31)
- Completion: 2016-02 (anticipated) (ClinicalTrials.gov record NCT02551172, source copy `cardio:ctgov-nct02551172-2015-09-16`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT02551172, source copy `cardio:ctgov-nct02551172-2015-09-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02551172-2015-09-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
- Condition: Hyperlipidemias
- Intervention (Drug): HCP1105
- Intervention (Drug): HGP0816
- Intervention (Drug): Placebo of HCP1105
- Intervention (Drug): Placebo of HGP0816
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 3a21816171d8a9c378495bbdb56ef418b29a23bcbceebd0bfc6863c5e2d7415d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
